This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cannabis Giant Tilray (TLRY) Skyrocketed Today
by Madeleine Johnson
Shares of Tilray (TLRY) closed sharply higher in Wednesday's trading session, gaining 25.8% after reporting mixed fourth-quarter earnings results.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $23.91, moving -0.87% from the previous trading session.
Forget Meme Stocks: Buy These Strong Growth Stocks with Big Upside
by Benjamin Rains
Investors might want to consider adding growth focused stocks to their portfolios that are still trading below their highs, even as the meme stocks soar once again...
Company News for Jun 2, 2021
by Zacks Equity Research
Companies In The News Are: ABT, CLDR, KKR, CGC, NIO.
Stocks Rise as Big Infrastructure Spending Looks Increasingly Likely.
by David Borun
Investors bet on the US economy as Congress contemplates $1 trillion or more in spending - and potential tax changes to pay for it.
New Strong Sell Stocks for June 1st
by Zacks Equity Research
AEYE, CGC, GCI, IVAC, and PSHG have been added to the Zacks Rank #5 (Strong Sell) List on June 1, 2021.
Canopy Growth Corporation (CGC) Stock Jumps 5.5%: Will It Continue to Soar?
by Zacks Equity Research
Canopy Growth Corporation (CGC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $22.68, moving -1.31% from the previous trading session.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $23.15, marking a +1.05% move from the previous day.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $23.91 in the latest trading session, marking a -1.12% move from the prior day.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $27.53, marking a +0.44% move from the previous day.
Tenet Healthcare's (THC) Q1 Earnings Surpass, Improve Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) first-quarter earnings gain from better revenues and impressive contributions from its Hospital operations and Ambulatory segments.
What's in Store for HCA Healthcare's (HCA) Q1 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter earnings are likely to have witnessed better patient volumes and improved revenues.
Canopy Growth Corporation (CGC) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Canopy Growth Corporation (CGC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Canopy Growth (CGC) Surges: Stock Moves 6.3% Higher
by Zacks Equity Research
Canopy Growth (CGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Cannabis Stocks Rise on Hopes of Federal Legalization in US
by Zacks Equity Research
Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.
The Zacks Analyst Blog Highlights: Canopy Growth, Tilray, Cisco Systems, Twitter and Lyft
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Canopy Growth, Tilray, Cisco Systems, Twitter and Lyft
Pot Stocks Take Markets Higher; Plus Beats for Cisco, Twitter, Lyft
by Mark Vickery
With Tilray (TLRY) +44% and Canopy (CGC) +12% on the day, the Nasdaq and Russell 2000 managed to climb to fresh all-time highs Tuesday.
Canopy Growth Corporation (CGC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -366.67% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $44.14 in the latest trading session, marking a -1.78% move from the prior day.
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.